The first generation of CSF biomarkers for Alzheimer disease comprises those that measure the component proteins of the disease’s signature pathologic lesions. They have been explored for almost 15 ...
Roche announced June 27 that the U.S. FDA has issued 510(k) clearance for the company's CSF Aβ42/total-tau assay to be used for the diagnosis of Alzheimer’s disease in people aged 55 and older. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results